Abstract: A process for purifying crude fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether (sevoflurane). The crude sevoflurane is repeatedly washed with water under conditions and for a time sufficient to reduce the level of 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) to no more than 200 ppm or no more than 100 ppm.

Abstract: A triple beam resonator (10) is provided with three beams or tines (12, 14, 16) aligned in parallel alongside each other and joined at a decoupling zone (18) at each end, which is in turn connected to the surrounding material. The central beam (14) is twice the width of the two outer beams (12, 16). The resonating element has a length of 15.5 mm, a thickness of 0.25 mm and beam widths of 2 mm and 1 mm. The distance between the beams is 0.5 mm. Finite element analysis predicts the modal behavior with stress distribution and eigenfrequencies of the resonator (10). Thick-film PZT elements (20, 22) were printed on separate regions at each end of the central beam (14), where maximum stresses exist as the resonator (10) operates in its favored mode of vibration. The PZT element (20) at one end drives the vibrations, while the PZT element (22) at the other end detects them.

Abstract: An azeotrope comprising desflurane (CF3CFHOCF2H) and hydrogen fluoride (HF). The azeotrope can be prepared by fractionally distilling a crude mixture of desflurane and HF. Purer desflurane can be readily and easily separated from the azeotrope. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

Abstract: Crude sevoflurane product comprising unacceptably high levels of HFIP can be purified by combining the crude sevoflurane product with sufficient water to produce a multiphase mixture, fractionally distilling the multiphase mixture, and removing substantially pure sevoflurane from the distilling multiphase mixture. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

Abstract: A process for preparing fluorinated ethers, such as desflurane, comprises reacting the corresponding chlorinated ether, such as isoflurane, with anhydrous hydrogen fluoride in the vapor phase in the presence of chromia catalyst. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

Abstract: Apparatus 10 comprises a receiver body 12 along with a trigger 14 for activating the firing mechanism and a lever 16 for opening the breech assembly to allow access to the chamber for receiving the shell/cartridge 56 at the rear of the barrel 18. The barrel 18 is secured to the breech 28 by an extension lug 58 having an internal transverse hole 61 therein which receives the extension lug pin 59 therein as the extension lug is inserted into the slot 60 on the top portion of the breech block 28 so that the breech can be opened and closed by lever 16. Also shown is the cartridge/shell 56 extractor 62 which comprises an extractor pin 68 along with an extractor spring 70. The barrel 18 comprises a front barrel support 64 and a rear barrel support 66 which each have a lower flange 65 thereon which slides to the front and rear in slot or track 67 in response to pressure from the barrel pin 72 and barrel spring 74 which occurs after the lever 16 is operated to free the barrel 18 from the breech block 28.

Abstract: Apparatus 10 discloses a receiver body 12 along with a trigger 14 for activating the firing mechanism and a lever 16 for opening the breech assembly to allow access to the chamber for receiving the shell/cartridge 56 at the rear of the barrel 18. FIG. 1 shows the breech block 28 and barrel 18 closed and FIG. 2 shows the breech block 28 and barrel 18 open. Also shown is the action bar 20 having a front portion for contacting the rear of the firing pin 22 and forcing the firing pin forward so as to contact the primer 55 of the shell/cartridge 56. The firing pin 22 has a firing pin spring 26 thereon which is mounted in a hole in the breech block 28. The action bar 20 is supported by upper and lower supports 30 near its front end along with upper and lower support pins 31 which also act as a rear spring stop near its mid-section having main spring 24 and front spring stop 25 thereon. Also shown on the action bar is internal, transverse slot 38 and notch 48 on its bottom surface.

Abstract: 1,1,1,3,3,3-Hexafluoroisopropanol (HFIP) substantially free of 1,1,1-trifluoroacetone (TFA) can be separated from a mixture containing both compounds by A) catalytic reduction with hydrogen followed by fractional distillation; B) cooling to a temperature at which HFIP freezes and TFA remains liquid; C) forming a high boiling complex comprising HF and TFA followed by fractional distillation; or D) producing HF-free conditions to yield a HFIP/TFA azeotrope followed by fractional distillation. It is emphasized that this abstract is provided to comply with the rules requiring an abstract, which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR § 1.72(b).

Abstract: The specification and drawings describe and show one preferred embodiment or a small number of preferred embodiments of the present invention in the form of a container constructed from or lined with a material comprising a copolymer of acrylonitrile, methyl acrylate, and butadiene, said container defining an interior space constructed to contain therein, external to a patient's body, an inhalation anesthetic; and a volume of sevoflurane contained in said interior space defined by said container. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

Abstract: A seat back cushion support presenting device for use in a foldable vehicle seat moves a cushion support member from a position within the seat back frame to a position extended from the seat back frame such that the entire cushion is presented. A pair of presenting members, each including a side bolster support portion, are provided in overlapping arrangement for translation along a presenting device support member and rotation with respect to a cushion support member such that as an activation member moves the presenting members together, the cushion support member is extended along with the side bolster support portions.

Abstract: Methods and products for stimulating hematopoietic, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and, mature blood cells are provided. The methods and products can be used both in vivo and in vitro.

Abstract: A method in which organic matter found in a crude sevoflurane may be separated, identified, and quantified using a CARBOWAX™ (polyethylene glycol) capillary gas chromatographic column or an alkyl polysiloxane capillary gas chromatographic column. Also provided is a process control method for the production of sevoflurane, wherein the content of a particular component in one of the following steps is determined, and in that, assuming this as a variable, the treatment condition of the step is adjusted: 1) a step of extracting, or cooling to form two layers, and/or distilling a mixture of crude sevoflurane and hydrogen fluoride (HF) in order to isolate the majority of the sevoflurane and 2) an optional step of purifying the crude sevoflurane and 3) a step of distilling crude sevoflurane. Also provided is a method for determining the impurity level of a purified sevoflurane that is acceptable for use in human/animal anesthesia.

Abstract: The invention relates to compositions of Glu-boroPro and methods of use thereof in the prevention or management of type 2 diabetes.

Abstract: A system for determining the condition of a device or process uses the inter-arrival times of successive acoustic emission events generated by the device or process being monitored. From this measurement, the system determines a statistical distribution, preferably a Weibull distribution, to determine a shape to life parameter for characterizing the device or process being monitored. The system allows a simple and effective determination of the condition of a device or process, taking into account operating conditions and which can monitor also the state of healthy components.

Abstract: Methods and products for stimulating hematopoiesis, preventing low levels of hematopoietic cells and producing increased numbers of hematopoietic and mature blood cells are provided. The methods and products can be used both in vivo and in vitro. The methods involve administering an agent of Formula I wherein m is an integer between 0 and 10, inclusive; A and A1 are L-amino acid residues such that the A in each repeating bracketed unit can be the same or a different amino acid residue; the C bonded to B is in the L-configuration; the bonds between A and N, A1 and C, and between A1 and N are peptide bonds; and each X1 and X2 is, independently, a hydroxyl group or a group capable of being hydrolyzed to a hydroxyl group in aqueous solution at physiological pH. The products include kits comprising the agent of Formula I.

Abstract: A seat back cushion support presenting device for use in a foldable vehicle seat moves a cushion support member from a position within the seat back frame to a position extended from the seat back frame such that the entire cushion is presented. A pair of presenting members, each including a side bolster support portion, are provided in overlapping arrangement for translation along a presenting device support member and rotation with respect to a cushion support member such that as an activation member moves the presenting members together, the cushion support member is extended along with the side bolster support portions.

Abstract: The invention relates, in part, to of Glu-boroPro containing compounds and methods of use thereof in the prevention or management of conditions that are associated with impaired glucose tolerance such as diabetes. The invention also relates to compositions of Glu-boroPro containing compounds and methods of use thereof in the prevention or management of conditions such as metabolic syndrome, dyslipidemias, inflammation, cardiovascular disorders such as hypertension and atherosclerosis, and to reduce body weight or prevent weight gain. The compounds of the invention are also useful in lowering levels of triglycerides, free fatty acids, C-reactive protein (CRP), HbA1C, total glycosylated hemoglobin (TGHb), in increasing insulin sensitivity index and in stimulating insulin release.

Abstract: The invention relates to compositions of Glu-boroPro and methods of use thereof in the prevention or management of type 2 diabetes.

Abstract: A method in which organic matter found in a crude sevoflurane may be separated, identified, and quantified using a CARBOWAX™ (polyethylene glycol) capillary gas chromatographic column or an alkyl polysiloxane capillary gas chromatographic column. Also provided is a process control method for the production of sevoflurane, wherein the content of a particular component in one of the following steps is determined, and in that, assuming this as a variable, the treatment condition of the step is adjusted: 1) a step of extracting, or cooling to form two layers, and/or distilling a mixture of crude sevoflurane and hydrogen fluoride (HF) in order to isolate the majority of the sevoflurane and 2) an optional step of purifying the crude sevoflurane and 3) a step of distilling crude sevoflurane. Also provided is a method for determining the impurity level of a purified sevoflurane that is acceptable for use in human/animal anesthesia.

Abstract: A method is provided for treating subjects with combination therapy including compounds of Formula I. It was surprisingly discovered that this combination enhanced the efficacy of both agents, and that administration of Formula I compounds induced cytokine and chemokine production in vivo. The combinations can be used to enhance ADCC, stimulate immune responses and/or patient and treat certain disorders. The invention also relates to kits and compositions relating to such combinations.